HC Wainwright Reaffirms Buy Rating for PDS Biotechnology (NASDAQ:PDSB)

PDS Biotechnology (NASDAQ:PDSB)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $13.00 price target on the stock.

Separately, Wall Street Zen raised PDS Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, May 24th.

PDS Biotechnology Stock Performance

PDSB stock opened at $1.79 on Wednesday. PDS Biotechnology has a twelve month low of $0.85 and a twelve month high of $4.42. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.55. The company has a market cap of $81.82 million, a P/E ratio of -1.54 and a beta of 1.27. The business’s fifty day moving average is $1.33 and its 200-day moving average is $1.47.

PDS Biotechnology (NASDAQ:PDSB) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.04. Equities research analysts forecast that PDS Biotechnology will post -1.2 EPS for the current year.

Hedge Funds Weigh In On PDS Biotechnology

Several institutional investors and hedge funds have recently made changes to their positions in PDSB. Armistice Capital LLC bought a new stake in shares of PDS Biotechnology in the 1st quarter valued at $5,259,000. Blair William & Co. IL grew its stake in PDS Biotechnology by 63.3% in the first quarter. Blair William & Co. IL now owns 257,200 shares of the company’s stock valued at $306,000 after acquiring an additional 99,700 shares during the period. Renaissance Technologies LLC increased its holdings in shares of PDS Biotechnology by 331.0% in the fourth quarter. Renaissance Technologies LLC now owns 100,000 shares of the company’s stock worth $163,000 after acquiring an additional 76,800 shares in the last quarter. Iron Gate Global Advisors LLC acquired a new stake in shares of PDS Biotechnology during the first quarter worth about $89,000. Finally, Virtu Financial LLC acquired a new stake in shares of PDS Biotechnology during the fourth quarter worth about $89,000. Institutional investors and hedge funds own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.